Secondary adrenal insufficiency caused by sorafenib administration in a patient with hepatocellular carcinoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Sorafenib (Nexavar) has been regarded as a treatment for unresectable hepatocellular carcinoma (HCC), with side effects that include hand-foot skin reaction, diarrhea, rash, fatigue, hypertension, nausea, anorexia, weight loss, and alopecia. Thyroid disorder, such as endocrine side effect, has also been reported. However no case involving adrenal insufficiency has been reported. Here, we report a case of adrenal insufficiency which occurred after taking sorafenib in a patient with HCC. A 56-year-old man visited our hospital due to right upper quadrant abdominal pain and he was diagnosed as multiple disseminated and unresectable HCCs with portal vein invasion; therefore transarterial chemoembolization was performed and sorafenib administration was started. Two months later, he was admitted to the hospital complaining of severe fatigue. The laboratory results showed cortisol of <0.2μ g/dL and adrenocorticotropic hormone of <1.00 pg/mL. The patient had no history of taking steroids or herbal medications. Secondary adrenal insufficiency was diagnosed and prednisolone 10 mg per day was started immediately; as a result, fatigue remarkably improved. This may be the first report indicating a possible association between sorafenib and adrenal insufficiency and it implies that the possibility of adrenal insufficiency should be considered in patients taking sorafenib who complain of severe fatigue.
Abstract
Sorafenib (Nexavar) has been regarded as a treatment for unresectable hepatocellular carcinoma (HCC), with side effects that include hand-foot skin reaction, diarrhea, rash, fatigue, hypertension, nausea, anorexia, weight loss, and alopecia. Thyroid disorder, such as endocrine side effect, has also been reported. However no case involving adrenal insufficiency has been reported. Here, we report a case of adrenal insufficiency which occurred after taking sorafenib in a patient with HCC. A 56-year-old man visited our hospital due to right upper quadrant abdominal pain and he was diagnosed as multiple disseminated and unresectable HCCs with portal vein invasion; therefore transarterial chemoembolization was performed and sorafenib administration was started. Two months later, he was admitted to the hospital complaining of severe fatigue. The laboratory results showed cortisol of <0.2μ g/dL and adrenocorticotropic hormone of <1.00 pg/mL. The patient had no history of taking steroids or herbal medications. Secondary adrenal insufficiency was diagnosed and prednisolone 10 mg per day was started immediately; as a result, fatigue remarkably improved. This may be the first report indicating a possible association between sorafenib and adrenal insufficiency and it implies that the possibility of adrenal insufficiency should be considered in patients taking sorafenib who complain of severe fatigue.
참고문헌 (11)
- Abdel-Rahman O., "Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside", J Egypt Natl Canc Inst, 25, pp.165~171 (2013)
- Keating GM, "Sorafenib: a review of its use in advanced hepatocellular carcinoma", Drugs, 69, pp.223~240 (2009)
- Feldt S, "Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study", Eur J Cancer, 48, pp.974~981 (2012)
- Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma, "Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements", J Gastroenterol Hepatol, 25, pp.657~663 (2010)
- Bruix J, "Chemoembolization for hepatocellular carcinoma", Gastroenterology, 127(5 Suppl 1), pp.S179~S188 (2004)
- Kim H, "Lipiodol-induced pneumonitis following transarterial chemoembolization for ruptured hepatocellular carcinoma", Yeungnam Univ J Med, 31, pp.117~121 (2014)
- Zhang L, "Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis", PLoS One, 9, pp.e100305~ (2014)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Abdel-Rahman O, "Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma:a systematic review of the literature", Crit Rev Oncol Hematol, 91, pp.1~8 (2014)
- Okushin K, "IGF-II producing hepatocellular carcinoma treated with sorafenib: metabolic complications and a foresight to molecular targeting therapy to the IGF signal", Case Rep Gastroenterol, 6, pp.784~789 (2012)